Work

The Vast Majority of CML-CP Patients Treated with Dasatinib (70 mg BID) Who Progress after Long-Term Follow-up (24 mo) Remain in Chronic-Phase

Year: 2008

Type: article

Source: Blood

DOI: 10.1182/blood.v112.11.4265.4265

Authors: Jorge Cortes, Michael Mauro, Susan O’Brien, Gautam Borthakur, William Wierda, Yousif Matloub, Ritwik Sinha, David Liu, Hagop Kantarjian

Institutions: The University of Texas MD Anderson Cancer Center, Oregon Health & Science University, Bristol-Myers Squibb (United States)

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2593675464

FWCI:

Cites:

Cited by: 2

Related to: 10